Skip to main content
NANJING VAZYME BIOTECH CO., LTD. logo

NANJING VAZYME BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 688105 ISIN · CNE100004ZK3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 523 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 688105

About NANJING VAZYME BIOTECH CO., LTD.

https://www.vazymeglobal.com/

Nanjing Vazyme Biotech Co., Ltd. focuses on the research, development, and manufacturing of high-performance enzymes and biological reagents. Utilizing proprietary protein engineering and directed evolution platforms, the company provides a comprehensive portfolio of products, including molecular biology reagents, NGS library preparation kits, and raw materials for in vitro diagnostics. Its offerings support critical applications in life science research, clinical medicine, and biopharmaceutical production. Vazyme specializes in the large-scale synthesis of high-purity proteins and the innovation of tools for nucleic acid amplification, sequencing, and detection. By delivering advanced solutions for genomics, proteomics, and synthetic biology, the company facilitates progress across the global scientific landscape.

Recent filings

Filing Released Lang Actions
诺唯赞2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 97% confidence The document is a formal stock exchange announcement detailing the 2025 year‐end equity distribution scheme for cash dividends (0.50 RMB per share) and share bonus (0.30 shares per share), including record date, ex‐dividend date, payment date, tax treatment, share capital changes, and implementation procedures. This clearly matches a "Notice of Dividend Amount" rather than a full financial report or other corporate event. Therefore it should be classified as DIV.
2026-05-25 Chinese
北京市天元律师事务所关于南京诺唯赞生物科技股份有限公司差异化分红事项的专项核查意见
Regulatory Filings Classification · 45% confidence The document is a special verification opinion issued by Tian Yuan Law Firm concerning the company’s differential dividend distribution scheme due to share repurchases. It is a legal compliance opinion, not a financial report (e.g., 10-K, IR), not an earnings release, dividend notice, or board change announcement. It represents a miscellaneous regulatory/legal filing by counsel. Under the classification rules, this falls under the fallback category "Regulatory Filings" (RNS).
2026-05-25 Chinese
诺唯赞关于2026年第一次临时股东会的延期公告
Regulatory Filings Classification · 90% confidence The document is a formal announcement by the board of Nanjing Vazyme Biotech Co., Ltd. about the postponement of the 2026 first extraordinary general meeting. It does not contain voting results, financial statements, proxy materials, or executive management changes—it simply notifies shareholders of a change in meeting date and details. There is no indication of dividends, financing, or substantive financial data. This type of regulatory notice falls under the general “Regulatory Filings” category as a fallback for miscellaneous compliance announcements.
2026-05-25 Chinese
诺唯赞关于中证中小投资者服务中心有限责任公司公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a public announcement by the China Securities Investor Service Center soliciting proxy voting rights ahead of a shareholder meeting, providing detailed instructions and materials for shareholders to grant their voting rights. This is a classic proxy solicitation communication, fitting the definition of “Proxy Solicitation & Information Statement” (PSI).
2026-05-19 Chinese
独立董事候选人声明与承诺（方雷）
Proxy Solicitation & Information Statement Classification · 75% confidence The document is a personal declaration and commitment by an independent director candidate (“独立董事候选人声明与承诺”) outlining qualifications and independence, which is typically included in proxy materials sent to shareholders when soliciting votes for board elections. It does not present financial data, nor is it an announcement of an actual board change; rather it provides information to shareholders to support the voting decision. This aligns with the Proxy Solicitation & Information Statement category.
2026-05-18 Chinese
董事会提名委员会关于第三届董事会董事候选人的审核意见
Board/Management Information Classification · 81% confidence The document is a written opinion from the Board Nomination Committee regarding the qualification review of proposed non-independent and independent director candidates for the company’s third board. It does not contain financial statements or earnings information, nor is it a full report; rather it is an announcement related to board composition and management changes. This fits the definition of Board/Management Information (MANG).
2026-05-18 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.